You are here
Second-Generation BCR-ABL Kinase Inhibitors in CML
CORRESPONDENCE Second-Generation BCR-ABL Kinase Inhibitors in CML; N Engl J Med 2010; 363:1672-1675October 21, 2010
nejm.org/toc/nejm/363/17/" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 3px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 3px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 1px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-weight: inherit; font-style: inherit; font-size: 11px; vertical-align: baseline; color: rgb(0, 104, 146); text-decoration: none; border-left-style: solid; border-left-color: rgb(153, 153, 153); ">October 21, 2010
see here for interesting questions and answers between international CML expert clinicians regarding issues of response to therapy guidelines from European Leukaemia Net as well as issues of data from clinical trials re: 2nd generation TKI's etc. If you scroll down you will find the responses to the questions.